Yakira Capital Urges Atrium Therapeutics to Review Strategy and Spending
Yakira Capital urged Atrium Therapeutics’ board to explore strategic alternatives, curb cash spending and explain its $50 million financing. The firm cited a roughly 44% share-price decline and a valuation near half of net cash.